Physician profile
Frank E Scott
NPI 1295877207
$20,954.32
in general payments reported to CMS, 2019-2025
31 companies · $2,250 in 2025
The $2,250 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,142 · 2020: $2,195 · 2021: $3,136 · 2022: $3,719 · 2023: $2,616 · 2024: $2,897 · 2025: $2,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,715 · Education: $48.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,714.79 |
| Education | $48.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,670.40 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,228.88 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Cardinal Health 108 LLC | $2,655.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,088.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,754.42 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Glaxosmithkline, LLC. | $740.99 | 2019-2025 | Benlysta |
| Pfizer INC. | $599.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $553.08 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $547.33 | 2019-2024 | |
| Lilly USA, LLC | $539.78 | 2019-2022 | |
| Horizon Therapeutics Plc | $510.92 | 2020-2023 | Krystexxa, Uplizna |
| Aurinia Pharma U.S., INC. | $465.65 | 2021-2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $254.17 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.04 | 2019-2025 | Orencia |
| Radius Health, INC. | $172.60 | 2019-2025 | Tymlos |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $135.19 | 2020-2024 | |
| Mallinckrodt Enterprises LLC | $131.29 | 2019 | |
| Mallinckrodt Hospital Products INC. | $129.06 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $124.72 | 2021 | |
| Fresenius Kabi USA, LLC | $79.00 | 2023-2024 | Idacio |
| Genentech USA, INC. | $58.40 | 2025 | Gazyva, Actemra |
| Sanofi-Aventis U.S. LLC | $52.99 | 2019 | |
| Ani Pharmaceuticals, INC. | $47.69 | 2025 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $44.33 | 2024-2025 | Teriparatide |
| Organon LLC | $31.63 | 2024-2025 | Hadlima, Renflexis |
| Teva Pharmaceuticals USA, INC. | $29.73 | 2024 | Simlandi |
| Octapharma USA, INC. | $25.83 | 2024 | Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2022 | |
| Ucb, INC. | $23.01 | 2021 | |
| Kyowa Kirin, INC. | $22.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.